Vivianna Diaz

Vivianna Diaz supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing mission-critical procurement activities that advance regulatory science and sustain high-precision scientific infrastructure. She manages acquisitions for research and development services essential to evaluating the safety, efficacy, and security of pharmaceuticals, biological products, and medical devices. Her work centers on securing specialized scientific consulting, laboratory support, and analytical instrumentation services that directly enable FDA’s regulatory decision-making and public health oversight. Diaz’s portfolio is strategically aligned with the agency’s priorities in maintaining cutting-edge research capabilities and ensuring continuity of critical laboratory operations. She maintains consistent working relationships with key contractors including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., all of which provide specialized scientific, clinical, and toxicological research services. These partnerships reflect a focus on niche, high-expertise vendors capable of delivering complex, compliance-driven scientific support under stringent regulatory frameworks. Her contracting patterns indicate a preference for established contractors with proven track records in FDA-regulated environments, ensuring technical rigor and regulatory alignment in service delivery. Diaz’s acquisition strategy reflects a balanced approach to socioeconomic contracting, with approximately equal portions of awards issued under total small business set-asides and open competitions without set-asides. This pattern underscores a deliberate commitment to fostering small business participation while maintaining flexibility to secure mission-critical expertise from the most qualified sources. Her contracting practices align with FAR 19.5 guidelines, consistently prioritizing small business vendors in eligible categories without favoring specific socioeconomic designations such as 8(a), HUBZone, or SDVOSB. Her primary procurement focus is exclusively under NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—encompassing contract research organizations, analytical testing services, and scientific advisory support. She procures specialized services including toxicology studies, clinical trial support, biomarker validation, and laboratory instrumentation maintenance, all essential to FDA’s regulatory science mission. Her expertise lies in navigating the technical complexities of life sciences R&D procurement to ensure scientifically sound, compliant, and operationally reliable outcomes.